Home · Health · Sep 28 archive
Merck Discontinues Key Antibiotic Amid Superbug Concerns
Developing
In Short: Merck recently discontinued Recarbrio, a three-drug combination antibiotic injection, from the U.S. market, STAT reports. The company did not provide a reason for the decision.
Merck recently discontinued Recarbrio, a three-drug combination antibiotic injection, from the U.S. market, STAT reports. The company did not provide a reason for the decision.
Recarbrio was designated as a treatment of last resort by the FDA to help prevent antibiotic resistance, a growing public health concern.
The discontinuation of Recarbrio highlights the challenges in maintaining a robust arsenal of antibiotics against increasingly resistant superbugs.
Merck did not disclose the sales figures for Recarbrio in its regulatory filings, leaving the financial impact of the decision unclear.
What this adds
The lack of transparency from Merck regarding the discontinuation and sales figures adds to the uncertainty surrounding the future of antibiotic development and availability.
What's still developing
- Test your knowledge with our new weekday mini crossword In an unexpected move, Merck discontinued an important antibiotic from the U.S. market earlier this month, underscoring concerns about the commitment large pharmaceutical companies are willing to make to a field that is crucial to public health.
- To read the rest of this story subscribe to STAT+.
- You may opt out of receiving STAT communications at any time.